Bermekimab is under clinical development by Johnson & Johnson and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bermekimab’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 23 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bermekimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bermekimab overview

Bermekimab (Xilonix) is under development for atopic dermatitis. The drug candidate is administered through intravenous and subcutaneous routes. Xilonix is acts by targeting Interleukin 1 alpha. It was also under development for the treatment of unspecified indication, cachexia in patients with advanced colorectal cancer, relapsed/refractory acute myeloid leukemia, relapsed/refractory acute lymphocytic leukemia, relapsed/refractory chronic lymphocytic leukemia (CLL), relapsed/refractory chronic myelocytic leukemia, hidradenitis suppurativa, arterial thrombosis, non-small cell lung cancer, restenosis (Peripheral vascular disease) in patients undergoing percutaneous femoropopliteal revascularization, skin ulcers including pyoderma gangrenosum, moderate to severe plaque psoriasis, type 2 diabetes mellitus, acne vulgaris, systemic scleroderma, advanced pancreatic cancer with cachexia and ovarian cancer. 

Natrunix is under development for the treatment of inflammatory joint diseases, including osteoarthritis and rheumatoid arthritis (RA).

Johnson & Johnson overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

Quick View Bermekimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Bermekimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Dermatology
  • Immunology
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Oncology
  • Undisclosed
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.